Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9644843 | 0.82 | GSK3B (0.76) | GSK3BALDH1A1CYP1A2TDP1L3MBTL1 | |
| SCHEMBL1714628 | 0.78 | CES2 (0.37) | GSK3BTDP1L3MBTL1CES2LMNA | |
| SCHEMBL4316411 | 0.76 | KDM4E (0.47) | GSK3BALDH1A1CYP1A2TDP1L3MBTL1 | |
| SCHEMBL27994581 | 0.76 | PDPK1 (0.52) | GSK3BALDH1A1TDP1L3MBTL1CES2 | |
| SCHEMBL27677325 | 0.76 | CES2 (0.53) | ALDH1A1TDP1L3MBTL1CES2LMNA | |
| SCHEMBL379271 | 0.75 | GSK3B (0.60) | GSK3BALDH1A1TDP1L3MBTL1CES2 | |
| SCHEMBL8740775 | 0.75 | GSK3B (0.60) | GSK3BALDH1A1TDP1L3MBTL1CES2 | |
| SCHEMBL27643168 | 0.74 | LMNA (0.34) | GSK3BALDH1A1TDP1L3MBTL1CES2 | |
| SCHEMBL2096724 | 0.73 | GSK3B (0.64) | GSK3BCYP1A2CES2LMNACES1 | |
| SCHEMBL2962521 | 0.73 | GSK3B (0.64) | GSK3BALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436036-B2 | Diaryl ethers | JANSSEN R&D IRELAND (IE) | 2013-05-07 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034678-A1 | Diaryl Ethers | SLC10A1, CYP2F1, UGT1A1 | GSK3B 1310/4885ALDH1A1 325/4885CYP1A2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.